Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd
688336
Rangering i aksjer
#3772
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd functions as a... Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd functions as a biopharmaceutical enterprise operating in China. This company is thoroughly engaged in the full lifecycle of antibody-based medicines, from their initial research and development to their production and subsequent market introduction. Its current portfolio includes YISAIPU, a tumor necrosis factor inhibitor utilized for treating rheumatic ailments; Xenopax, a recombinant humanized anti-CD25 monoclonal antibody delivered via injection; and Cipterbin, an anti-HER2 monoclonal antibody. Furthermore, the organization is actively progressing novel treatments designed for autoimmune disorders, various cancers, and other health issues. Established in 2002, its main offices are situated in Shanghai, China.
Aksjekurs
$4.87
Markedsverdi
$4.36B
Endring (1 dag)
-5.47%
Endring (1 år)
-15.62%
Land
CN
Handel Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd (688336)
Kategori
Healthcare
Historikk for aksjesplitt for Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd (688336)
Aksjen Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd (symbol: 688336) har gjennomgått totalt 1 aksjesplitt.
Den nyeste splittelsen skjedde Jun 18, 2026.
Én 688336-aksje kjøpt før Jun 18, 2026 tilsvarer i dag 1.45 688336-aksjer.
Den nyeste splittelsen skjedde Jun 18, 2026.
Én 688336-aksje kjøpt før Jun 18, 2026 tilsvarer i dag 1.45 688336-aksjer.
Liste over aksjesplitt
| År | Splitt | Multiplikator | Kumulativ multiplikator |
|---|---|---|---|
| 2026-06-18 | 29:20 | x1.45 | x1.45 |
Aksjesplitt for lignende selskaper eller konkurrenter
| Selskap | Antall aksjesplitt | Kumulativ multiplikator | Land |
|---|---|---|---|
| 1 | x2 |
US
|
|
| 0 | - |
US
|
|
| 1 | x3 |
AU
|
|
| 1 | x100 |
BE
|
|
| 0 | - |
NL
|
